Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
BCMA CAR-T cell therapy
Idecabtagene vicleucel
Abecma · IDEC
A BCMA CAR-T whose AKI is IL-6-driven and prerenal — it reverses as the cytokine-release syndrome resolves.
ModerateBCMA CAR-T cell therapy · approved 2021
Relapsed or refractory multiple myeloma after prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody
Signature kidney injury
Prerenal / Hemodynamic AKI
Published CAR-T AKI incidence runs roughly 5-30% across cohorts and is mostly mild (KDIGO stage 1); in one cohort any-grade AKI reached ~30% by day 100 with rapid recovery. Most AKI parallels cytokine-release syndrome (CRS) and reverses within ~30 days.
Source: Gutgarts et al., Biol Blood Marrow Transplant 2020
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
Vasculature / EndotheliumGlomerular & peritubular capillaries
Proximal Tubule
Distal Tubule / Collecting Duct
Tubular Lumen
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
AKI is predominantly hemodynamic/prerenal, driven by cytokine-release syndrome. Activated CAR-T and bystander myeloid cells release IL-6 (the central mediator) plus IL-1, IFN-gamma and TNF-alpha, causing vasodilation, capillary leak, hypotension and reduced renal perfusion — prerenal/ischemic AKI that can progress to ATN if severe or prolonged. Secondary contributors include tumor lysis (uric acid and calcium-phosphate crystal nephropathy in high-burden disease), nephrotoxic antimicrobials/contrast, and lymphodepleting fludarabine/cyclophosphamide.
Clinical presentation
AKI typically arises on days 1-14, paralleling CRS onset (fever, hypotension, hypoxia), with a rising creatinine and low urine output; if tumor lysis is present, expect hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia and a high LDH.
Onset
Within the first 1-2 weeks (the CRS window).
Reversibility
Reversible
Anticancer mechanism
Autologous T cells transduced with a BCMA-directed chimeric antigen receptor (anti-BCMA scFv with 4-1BB costimulatory and CD3-zeta signaling domains). Binding to B-cell maturation antigen on malignant plasma cells triggers cytotoxic T-cell activation, proliferation and myeloma-cell lysis.
Management
Treat CRS with tocilizumab (anti-IL-6R) with or without corticosteroids, and support hemodynamics with IV fluids for the prerenal physiology. Manage tumor lysis (rasburicase, electrolyte correction). Renal replacement therapy is rarely needed; AKI usually reverses as CRS resolves.
Risk factors
- Grade >=3 CRS and ICU-level care
- Prior autologous/allogeneic stem-cell transplant
- Baseline CKD and high tumor burden
- Volume depletion
Prevention
- Tumor-lysis prophylaxis (hydration, allopurinol; rasburicase if high-risk)
- Avoid nephrotoxins and use judicious fluids
- Renally dose-reduce lymphodepleting fludarabine
- Early CRS recognition and treatment
Note · Frontier-era 2021 therapy; the renal signal is CRS/IL-6-mediated prerenal AKI, supported by dedicated CAR-T onconephrology cohorts.
Clinical depth
Renal dose adjustment
No CAR-T dose adjustment for renal function (it is a fixed cell product); the renal-relevant lever is the conditioning regimen, where fludarabine requires renal dose consideration. Cohort data show CAR-T is feasible even with reduced renal function or on dialysis.
Dialyzability & ESKD dosing
Not applicable — a living-cell product. Dialysis is used to support AKI/tumor lysis, not to remove the therapy.
Differential diagnosis
Tumor lysis versus prerenal CRS-AKI versus ATN versus fludarabine/contrast nephrotoxicity versus sepsis-associated AKI. Timing relative to CRS and the metabolic panel usually identify the dominant mechanism.
Monitoring
- Daily creatinine, electrolytes, uric acid and LDH during the CRS window
- CRS and ICANS grading (ASTCT criteria)
- Volume status and blood pressure
Key trials & series
- KarMMa (Munshi, NEJM 2021) — pivotal phase 2 registrational trial
- Gutgarts CAR-T AKI cohort (Biol Blood Marrow Transplant 2020) — incidence and rapid recovery
Clinical pearls
- IL-6 is the linchpin — CRS-AKI is largely prerenal and reverses as CRS resolves.
- Tocilizumab treats CRS but penetrates the CNS poorly, so it does not treat ICANS.
- Pre-existing CKD or dialysis is not an absolute contraindication to CAR-T.
- Published CAR-T AKI incidence is ~5-30%, mostly mild (KDIGO stage 1).
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIAcute Tubular NecrosisElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bcma car-t cell therapys.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.Munshi NC et al. · N Engl J Med 2021 · PMID 33626253KarMMa pivotal phase 2 registrational trial.PMIDAcute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.Gutgarts V et al. · Biol Blood Marrow Transplant 2020 · PMID 32088364Renal cohort: any-grade AKI ~30% by day 100, mostly grade 1, with recovery within 30 days; grade 3-4 CRS a risk factor.PMIDAcute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes.Vincendeau M et al. · Clin Kidney J 2024 · PMID 38915438Onconephrology AKI cohort describing patterns, management and outcomes.PMIDOutcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.Wood AC et al. · Transplant Cell Ther 2022 · PMID 36174934Feasibility and outcomes of CAR-T in reduced renal function and dialysis.PMIDCAR T-cell therapy and the onco-nephrologist.Salvino MA et al. · Front Nephrol 2024 · PMID 38706889Onconephrology review of CAR-T kidney complications and management.PMIDASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Lee DW et al. · Biol Blood Marrow Transplant 2019 · PMID 30592986Standard CRS/ICANS grading framework underpinning toxicity management.
Related agents
Other agents sharing the same signature kidney injury.